Wednesday, July 8, 2020, 5:00 PM – 6:00 PM ET

Recent Advances in Medical Oncology: HER2-Positive Breast Cancer

A Live Webinar Series Held in Conjunction with ASCO20 Virtual


Lisa A Carey, MD
Richardson and Marilyn Jacobs Preyer
Distinguished Professor for Breast Cancer Research
Deputy Director for Clinical Sciences
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Ian E Krop, MD, PhD
Associate Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Module 1: Available Data Sets Shaping the Management of Localized HER2-Positive Breast Cancer

  • Clinical trial data supporting the FDA approval of T-DM1 as adjuvant therapy for patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant therapy
  • Available research evaluating novel adjuvant treatment approaches with T-DM1 for localized HER2-positive breast cancer
  • Phase III data with, FDA approval of and patient selection for pertuzumab as a component of adjuvant chemobiologic therapy
  • Optimal integration of postadjuvant neratinib into clinical algorithms; patient selection and clinical factors guiding its use in practice
  • Prevention, recognition and management of adverse events with postadjuvant neratinib

Module 2: Therapeutic Decision-Making for Patients with HER2-Positive Metastatic Breast Cancer (mBC)

  • Available efficacy and safety findings with tucatinib combined with trastuzumab/capecitabine for patients with HER2-positive mBC; CNS penetrability and activity of tucatinib in patients with brain metastases
  • Structure of and key research findings with the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive mBC; available efficacy data with this agent in patients with HER2-low advanced breast cancer
  • Neratinib/capecitabine for patients who have experienced disease progression on HER2-directed therapy for HER2-positive mBC
  • Recent FDA approvals of neratinib/capecitabine, trastuzumab deruxtecan and tucatinib/trastuzumab/capecitabine and optimal integration into practice for patients with and without brain metastases
  • Incidence, identification and management of toxicities associated with novel therapeutic strategies employed in the care of patients with progressive HER2-positive mBC
  • Ongoing evaluation of other novel agents and strategies under development for patients with HER2-positive mBC

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of specific therapeutic regimens for patients with HER2-overexpressing localized breast cancer, and integrate this information into current treatment decision-making.
  • Appraise available and emerging research evidence to individualize the selection of adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Evaluate the key research data with and the recent FDA approval of tucatinib with trastuzumab/capecitabine for patients with advanced HER2-positive breast cancer.
  • Develop an understanding of the mechanism of action of trastuzumab deruxtecan and the pivotal clinical trial findings leading to its FDA approval for patients with previously treated advanced HER2-positive breast cancer.
  • Assess clinical research on the FDA-approved combination of neratinib and capecitabine for patients with HER2-positive metastatic breast cancer.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, and consider how to optimally integrate neratinib/capecitabine, trastuzumab deruxtecan and tucatinib/trastuzumab/capecitabine into practice for the care of patients with and without CNS metastases.
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for metastatic HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Carey has no relevant conflicts of interest to disclose. The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr KropConsulting Agreements: Context Therapeutics, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Roche Laboratories Inc, Taiho Oncology Inc; Contracted Research: Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Puma Biotechnology Inc and Seattle Genetics.